D. A. Flockhart

787 total citations
20 papers, 554 citations indexed

About

D. A. Flockhart is a scholar working on Pharmacology, Oncology and Genetics. According to data from OpenAlex, D. A. Flockhart has authored 20 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 7 papers in Oncology and 6 papers in Genetics. Recurrent topics in D. A. Flockhart's work include Pharmacogenetics and Drug Metabolism (12 papers), Estrogen and related hormone effects (5 papers) and Cancer Treatment and Pharmacology (5 papers). D. A. Flockhart is often cited by papers focused on Pharmacogenetics and Drug Metabolism (12 papers), Estrogen and related hormone effects (5 papers) and Cancer Treatment and Pharmacology (5 papers). D. A. Flockhart collaborates with scholars based in United States, Switzerland and Sweden. D. A. Flockhart's co-authors include Zereunesay Desta, Jessica R. Oesterheld, Thomas Kerbusch, Therése Andersson, Deanna L. Kroetz, Mark J. Ratain, Shiew‐Mei Huang, Daniel A. Goldstein, Zeruesenay Desta and Patrice M. Milos and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Pharmacology & Therapeutics.

In The Last Decade

D. A. Flockhart

20 papers receiving 533 citations

Peers

D. A. Flockhart

PHARM

ONCOL

GENET

PPCH

Fernanda Rodrigues‐Soares Brazil

M.E.G. Naranjo Spain

Alison E. Fohner United States

Srikanth C. Nallani United States

Martha Sosa‐Macías Mexico

Jane Sayi Tanzania

Ingrid Fricke-Galindo Mexico

Alberto Chiappe Switzerland

James J. Ferry United States

Wim J. Tamminga Netherlands

Fernanda Rodrigues‐Soares Brazil

D. A. Flockhart

307 ×1.1

PHARM

113 ×0.9

ONCOL

111 ×1.0

GENET

97 ×1.1

PPCH

89 ×1.1

Citations per year, relative to D. A. Flockhart D. A. Flockhart (= 1×) peers Fernanda Rodrigues‐Soares

Countries citing papers authored by D. A. Flockhart

Since Specialization

Citations

This map shows the geographic impact of D. A. Flockhart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. A. Flockhart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. A. Flockhart more than expected).

Fields of papers citing papers by D. A. Flockhart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. A. Flockhart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. A. Flockhart. The network helps show where D. A. Flockhart may publish in the future.

Co-authorship network of co-authors of D. A. Flockhart

This figure shows the co-authorship network connecting the top 25 collaborators of D. A. Flockhart. A scholar is included among the top collaborators of D. A. Flockhart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. A. Flockhart. D. A. Flockhart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Decker, Brian S., Joanne S. Carpenter, D. A. Flockhart, et al.. (2014). Prerequisites to Implementing a Pharmacogenomics Program in a Large Health-Care System. Clinical Pharmacology & Therapeutics. 96(3). 307–309. 34 indexed citations

Rae, James M., Matthew J. Sikora, N. Lynn Henry, et al.. (2009). Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. The Pharmacogenomics Journal. 9(4). 258–264. 63 indexed citations

Aubert, Ronald E., J. Russell Teagarden, Milayna Subar, et al.. (2009). Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Journal of Clinical Oncology. 27(18_suppl). CRA508–CRA508. 17 indexed citations

Aubert, Ronald E., Jing Yao, J. Russell Teagarden, et al.. (2009). Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Journal of Clinical Oncology. 27(18S). CRA508–CRA508. 14 indexed citations

Stearns, Vered, Daniel F. Hayes, Jason Robarge, et al.. (2007). Tamoxifen-induced hot flashes are associated with estrogen receptor polymorphisms. Journal of Clinical Oncology. 25(18_suppl). 501–501. 2 indexed citations

Andersson, Therése, D. A. Flockhart, Daniel A. Goldstein, et al.. (2005). Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clinical Pharmacology & Therapeutics. 78(6). 559–581. 102 indexed citations

Stearns, Vered, Michael D. Johnson, James M. Rae, et al.. (2004). RESPONSE: Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine. JNCI Journal of the National Cancer Institute. 96(11). 884–885. 3 indexed citations

Azuma, J., Ulrich Brinkmann, D. A. Flockhart, et al.. (2004). Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network—REFARGEN. 1 indexed citations

Rustgi, Vinod K., et al.. (2002). Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics. 16(2). 235–242. 5 indexed citations

10.

Desta, Zereunesay, et al.. (2002). The Gastroprokinetic and Antiemetic Drug Metoclopramide Is a Substrate and Inhibitor of Cytochrome P450 2D6. Drug Metabolism and Disposition. 30(3). 336–343. 86 indexed citations

11.

Nikoloff, D M, Nancy Patten, Bonnie A. Fijal, et al.. (2002). Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. The Pharmacogenomics Journal. 2(6). 400–407. 27 indexed citations

12.

Winer, EP, et al.. (2001). Phase II Evaluation Of Thalidomide In Patients With Metastatic Breast Cancer. Journal of the Peripheral Nervous System. 6(1). 65–66. 1 indexed citations

13.

Flockhart, D. A. & Jessica R. Oesterheld. (2000). Cytochrome P450-Mediated Drug Interactions. Child and Adolescent Psychiatric Clinics of North America. 9(1). 43–76. 88 indexed citations

14.

Desta, Zereunesay, Thomas Kerbusch, & D. A. Flockhart. (1999). Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clinical Pharmacology & Therapeutics. 65(1). 10–20. 92 indexed citations

15.

Thacker, David, et al.. (1999). Metabolism of an anabolic androgenic steroid oxymetholone by human cytochrome P450s. Clinical Pharmacology & Therapeutics. 65(2). 136–136. 2 indexed citations

16.

Shin, Jae‐Gook, et al.. (1999). Haloperidol metabolites inhibit CYP2D6 catalyzed dextromethorphan O-demethylation in vitro. Clinical Pharmacology & Therapeutics. 65(2). 143–143. 1 indexed citations

17.

Desta, Zereunesay, David Thacker, Nadia Soukhova, Jennifer H. Shin, & D. A. Flockhart. (1999). Identification and characterization of human cytchrome P450 (CYP) isoforms interacting with cisapride. Clinical Pharmacology & Therapeutics. 65(2). 126–126. 2 indexed citations

18.

Donahue, Stephen, Jerry M. Collins, D. A. Flockhart, D. R. Abernethy, & Carol Braun Trapnell. (1997). Thalidomide pharmacokinetics do not change with chronic administration. Clinical Pharmacology & Therapeutics. 61(2). 3 indexed citations

19.

Yasuda, Sanae, et al.. (1995). Stereoselective inhibition of CYP2D6 by chlorpheniramine. Clinical Pharmacology & Therapeutics. 57(2). 149. 6 indexed citations

20.

Clauw, Daniel J., et al.. (1994). Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements.. PubMed. 21(12). 2385–7. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact